ClinicalTrials.gg
RecruitingNCT06923150MINIGOUpdated Apr 11, 2025

A Randomised Clinical Investigation to Assess Efficacy of Low Volume Transanal Irrigation by Qufora® IrriSedo MiniGo Versus Conservative Treatment for Low Anterior Resection Syndrome Patients

An observational study in Gastroenterology, LARS - Low Anterior Resection Syndrome and Rectal Cancer, sponsored by Qufora A/S. Recruiting at 9 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-11.

Sponsored by Qufora A/S · Observational

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
78
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this post-market clinical follow up study is to assess the efficacy on clinical symptoms of LARS of low volume Transanal Irrigation by MiniGo in conjunction with conservative treatment versus conservative treatment at 3 months.

02

Conditions studied

  • Gastroenterology
  • LARS - Low Anterior Resection Syndrome
  • Rectal Cancer

Keywords

  • LARS
  • Transanal Irrigation
  • Minigo
  • rectal cancer
03

In context

Low Anterior Resection Syndrome

82 studies on the registry are indexed under Low Anterior Resection Syndrome; 38 are open to participants now.

This study's planned enrollment of 78 is below the median of 125 across 25 observational studies indexed under Low Anterior Resection Syndrome.

Browse Low Anterior Resection Syndrome studies →

Lead sponsor

Qufora A/S is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

minor and major LARS patients LARS score >= 25

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult aged from 18 years
  2. Patients electively treated for rectal cancer with a low anterior resection
  3. Between 3 and 18 months after the conservative colorectal surgery or 3 and 18 months after the stoma reversal if applicable
  4. LARS score >= 25 (minor or major LARS) (Emmertsen and Laurberg 2012) AND LARS definition as consensus with at least one symptom that results in at least one consequence (Keane et al. 2020)
  5. Adult for whom previous conservative treatments were started for at least a month
  6. Mental and physical capability of the patient to handle the MiniGo by himself.
  7. Check of the anastomosis (no signs of leakage or clinical relevant stenosis) and absence of local recurrence by Rectal digital examination of the anastomosis, any other exam used in the current practice
  8. Patient affiliated to the health social security system

Exclusion criteria

Exclusion Criteria:

  1. to use TAI
  2. Former use of TAI (post colo-rectal surgery)
  3. stenosis
  4. Current disease or local recurrence
  5. Ongoing chemotherapy
  6. Postoperative radiotherapy for rectal cancer
  7. History of diarrhoeal disease
  8. Inflammatory bowel disease
  9. Dementia
  10. Spinal cord injury, multiple sclerosis, Parkinson's disease or other significant disease assessed to be a contributory cause to LARS symptoms.
  11. Patient with cancer recurrence
  12. Patient with a \< 1 year
  13. Participating to another clinical trial for the treatment of LARS symptom
  14. Ongoing pelvic floor rehabilitation/biofeedback
  15. Pregnancy or intention to become pregnant during the trial period
  16. Inability and unwillingness to give
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
78 participants (estimated)
Patient registry
No

Groups and cohorts

  • TAI + SOC

    Low volume TAI MiniGo + Standard of Care (SOC) conservative treatments

  • SOC

    Standard of Care (SOC) conservative treatments: dietary management, counselling, medication: anti-diarrheic or constipation treatment according to the prescription following usual practice, and food supplement excluding: suppository, ano-rectal stimulation, physiotherapy small enemas, etc...

06

What researchers measure

Primary outcomes

  1. LARS score difference

    The primary endpoint is defined by the LARS score difference between inclusion and 3-month follow-up for each randomisation group.

    Time frame: 3-month follow-up

Secondary outcomes

  1. efficacy on clinical symptom of transanal Irrigation by MiniGo in improving the LARS score at 6 weeks

    LARS difference score between inclusion and 6-week follow-up will be calculated for each randomised arm using descriptive statistics and confidence intervals

    Time frame: 6-week follow-up

  2. QoL with the EORTC QLQ-C30 EORTC QLQ-CR29

    EORTC-QLQ-C30 and EORTC-QLQ-CR29 differences scores between inclusion and 3-month follow-up will be calculated for each randomised arm using descriptive statistics and confidence intervals. Also, statistical tests of superiority will be performed comparing EORTC-QLQ-C30 and EORTC-QLQ-CR29 differences between inclusion and 3-month follow-up between interventional arm and control arm

    Time frame: 3-month follow- up

  3. change (reduction) of symptoms and consequences

    To assess the number of patients showing a change (reduction) of symptoms and consequences, as stated in the consensus definition at 6 and 12 weeks The number and the proportion of patients with each item of the LARS international consensus definition at 6 and 12 weeks will be calculated. Also, the proportion of patients who are considered as having no LARS at 6 and 12 weeks will be calculated with a confidence interval

    Time frame: 6 weeks and 12 weeks

  4. patient satisfaction

    to assess the patient satisfaction at 6 and 12 weeks, The proportion of patients satisfied by the treatment evaluated with the 5-point Likert Scale at 6 and 12 weeks will be calculated with a confidence interval.

    Time frame: 6 weeks and 12 weeks

  5. compliance of the patient to the treatmen

    to assess the compliance of the patient to the treatment at 6 and 12 weeks Compliance with the treatment during the 6 and 12 weeks of study with the number of days of MiniGo use per week will be calculated using descriptive statistics and confidence intervals

    Time frame: 6 weeks and 12 weeks

  6. incontinence anal score

    To access the incontinence anal score at 12 weeks Wexner difference score between inclusion and 12-week follow-up will be calculated for each randomised arm using descriptive statistics and confidence intervals. Also, statistical tests of superiority will be performed comparing Wexner differences between inclusion and 12-week follow-up between interventional arm and control arm.

    Time frame: 12 weeks

  7. reduction of defecations per day and night

    To assess the reduction of defecations per day and night The mean number of defecations per day and per night during the week before the randomisation and the week before the follow-up visit at 6 and 12 weeks will be calculated.

    Time frame: 6 weeks and 12 weeks

  8. time spent on bowel management (in the toilets room)

    To assess the time spent on bowel management (in the toilets room) Mean times spent in the toilets room per day the week before the randomisation and the week before the follow-up visit at 12 weeks will be calculated using descriptive statistics.

    Time frame: 12 weeks

  9. patient health organization and resources needed

    To evaluate the patient health organization and resources needed at 12 weeks Data about quantity of organization and resources needed (professional activities, treatment, medical and specialize consultation, home helpers) will be presented using descriptive statistics.

    Time frame: 12 weeks

  10. improving the LARS score

    to assess the efficacy on clinical symptom of Transanal Irrigation by MiniGo in improving the LARS score at 6, 9 and 12 months LARS difference score between inclusion and 6, 9 and 12-month follow-ups will be calculated using descriptive statistics and confidence intervals.

    Time frame: 6, 9 and 12 months

  11. number of patients showing a change (reduction) of symptoms and consequences

    To assess the number of patients showing a change (reduction) of symptoms and consequences, as stated in the consensus definition at 6, 9 and 12 months The number and the proportion of patients with each item of the LARS international consensus definition at 6, 9 and 12 months will be calculated. Also, the proportion of patients who are considered as having no LARS at 6, 9 and 12 months will be calculated with a confidence interval.

    Time frame: 6, 9 and 12 months

  12. Preference of the patient and reason for it

    To assess the preference of the patient and reason for it Proportion of patients who stay on TAI treatment for TAI arm and proportion of patients from SOC arm whose tries and stay on TAI will be calculated using confidence intervals. Description of reasons will be also presented.

    Time frame: 12 month follow-up

  13. QoL with the EORTC QLQ-C30 and EORTC QLQ-CR29 at 12 month

    to assess the QoL with the EORTC QLQ-C30 and EORTC QLQ-CR29 EORTC-QLQ-C30 and EORTC-QLQ-CR29 differences scores between inclusion and 12-month follow-ups will be calculated for each randomised arm using descriptive statistics and confidence intervals.

    Time frame: 12-month follow-up

  14. incontinence anal score at 12 months

    Wexner difference score between inclusion and 12-month follow-up will be calculated for each randomised arm using descriptive statistics and confidence intervals. Also, statistical tests of superiority will be performed comparing Wexner differences between inclusion and 12-month follow-up between interventional arm and control arm

    Time frame: 12-month follow-up

  15. patient health organization and resources needed at 6, 9 and 12 months

    Data about quantity of organization and resources needed (professional activities, treatment, medical and specialize consultation, home helpers) will be presented using descriptive statistics

    Time frame: 6, 9 and 12 months

07

Study locations

6 of 9 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Dec 2026, 30 months after the start.

Of 18 observational studies under Low Anterior Resection Syndrome, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 34. This study's planned 30 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2025
First posted
Apr 11, 2025
StartActual
Jun 18, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Apr 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06923150
Lead sponsor
Qufora A/S
Collaborators
EVAMED
Responsible party
Sponsor
First posted
Apr 11, 2025
Start date
Jun 18, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Apr 11, 2025

Study contacts

Rogini Balachandran
Contact
rob@qufora.com
+ 45 42 40 06 20

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion